Cipla Therapeutics, a division of Cipla USA, Inc., an affiliate of Cipla and SIGA Technologies Inc., a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.
The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.
S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs, said Garrett Ingram, CEO of Cipla Therapeutics and added AMR is a global priority for Cipla and our continued investment in this area along with SIGA's drug development and US experience creates a unique and strong partnership.
The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity which puts at risk the effective prevention and treatment of a wide range of infections.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU